Wegovy vs. Zepbound: Which One Actually Wins in 2026?

Which is better for weight loss — Wegovy or Zepbound?

The question got a real answer in May 2025, when SURMOUNT-5 became the first trial to put semaglutide and tirzepatide head-to-head in the same protocol instead of comparing separate trials run years apart. Published in the New England Journal of Medicine, it randomized adults with obesity to one drug or the other for 72 weeks. Tirzepatide — Zepbound's active ingredient — produced a mean weight loss of about 20% of starting body weight, versus about 14% for semaglutide, Wegovy's active ingredient. Waist circumference fell further on tirzepatide too, and a noticeably larger share of that group reached the higher weight-loss thresholds researchers track.

One update matters if you're comparing today. That trial ran semaglutide at 2.4mg, the top Wegovy strength available at the time; in March 2026 the FDA approved a 7.2mg dose that reached about 20.7% average weight loss in a trial of its own. It's a step up rather than a starting point — cleared for women who have already tolerated 2.4mg for a month and still have weight to lose — and the two results come from separate trials with different participants, so the honest read is that Wegovy's newer dose narrows Zepbound's lead rather than erasing it.

Those are trial averages, not a promise for any one person — dose, adherence, diet, and individual physiology all move the number. But on the specific question of average effect size in a direct comparison, Zepbound still holds the only head-to-head win between the two. For the deeper mechanism-level breakdown of why the two molecules diverge this much, semaglutide vs. tirzepatide covers that ground in full; this page stays focused on what it means for the Wegovy-versus-Zepbound brand decision specifically.

What's the actual difference between Wegovy and Zepbound?

Wegovy is Novo Nordisk's brand name for semaglutide, a molecule that acts on a single hormone receptor, GLP-1, slowing digestion and quieting appetite signals in the brain. Zepbound is Eli Lilly's brand name for tirzepatide, which does that same GLP-1 work but adds a second receptor, GIP — sometimes called a "twincretin" mechanism — that appears to compound the appetite and metabolic effect. That extra receptor is the leading explanation for the SURMOUNT-5 gap above, though exactly how much comes from the added receptor versus the specific doses studied is still being worked out.

Their FDA-approved uses have also diverged beyond simple weight management. Wegovy picked up a second indication in March 2024 — reducing cardiovascular risk in adults with established heart disease and overweight or obesity, based on the SELECT trial's finding of a real reduction in heart attack, stroke, and cardiovascular death. Zepbound picked up its own second indication in December 2024: moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication approved for that use at all. Neither drug's second indication substitutes for the other's.

One more structural difference is newer and easy to miss if you're working from an older comparison: as of January 2026, Wegovy is also FDA-approved as a once-daily oral tablet, in 1.5mg, 4mg, 9mg, and 25mg strengths, alongside its original weekly injection. It's the first oral GLP-1 approved for weight management. Zepbound has no equivalent — it remains injection-only, as a single-dose vial or a prefilled KwikPen. If avoiding needles is a real requirement for you, that's a genuine point in Wegovy's favor right now, not a marketing detail.

Wegovy vs. Zepbound: which costs less, all-in?

Wegovy is cheaper at essentially every tier that doesn't involve a savings card. Where insurance covers the drug and the manufacturer's card applies, the two converge at the same $25 figure — cost stops differentiating them entirely at that point. Everything below that tier, Wegovy wins.

NovoCare's Wegovy self-pay ladder

Novo Nordisk's own self-pay program, run directly through NovoCare, prices new patients at $199 a month for the lower-dose injection through the end of 2026, stepping up to $349 a month for standard doses and $399 for the highest injectable strength. A separate ladder covers the oral tablet, running roughly $149 to $299 a month depending on strength — often the single cheapest brand-name option on this page if a pill works for you.

LillyDirect's Zepbound self-pay ladder

Eli Lilly runs the equivalent program for Zepbound through LillyDirect: $299 a month at the 2.5mg starter dose, $399 at 5mg, and a flat $449 across every dose from 7.5mg through 15mg — vial and KwikPen priced the same. The catch is a 45-day refill window: complete your next order within 45 days of your last delivery, or the price resets higher for that fill. At its own maintenance tier, Zepbound's self-pay price runs about $100 a month above Wegovy's standard self-pay rate.

Retail pricing tells a similar story without any program at all. Wegovy's list price for the injection runs well over $1,300 a month, though GoodRx now discounts the oral tablet down into the $150–$300 range. Zepbound's retail and GoodRx coupon prices cluster close together, around $1,000 to $1,100 a month, because Lilly's contracts with discount-card programs keep the markdown shallow — a coupon rarely beats the manufacturer's own self-pay rate for either drug. For the full pathway-by-pathway numbers on each molecule, see Wegovy cost and Zepbound cost.

• Wegovy self-pay (standard tier), annualized: roughly $4,188/year at $349/mo.
• Zepbound self-pay (maintenance tier), annualized: roughly $5,388/year at $449/mo — about $1,200 more per year than Wegovy's equivalent tier.
• Either drug, insured with the savings card: roughly $300/year at $25/mo — the gap disappears entirely at this tier.

Does insurance cover Wegovy or Zepbound more easily?

Neither drug has a universal coverage edge — it comes down to your specific plan, and that answer can change year to year. Prior authorization is the norm either way: the large majority of insured patients seeking either drug face a PA requirement, typically documenting BMI, a qualifying comorbidity, and often a prior attempt at lifestyle treatment. Employer size matters too. Larger employers are considerably more likely to cover either drug for obesity than small ones, and coverage has been expanding unevenly across plan sizes.

Formulary tilt is real and it swings. CVS Caremark dropped Zepbound from its standard commercial formulary in mid-2025 in favor of Wegovy, then announced Zepbound would return to standard formularies in late 2026 — a change reported to affect tens of millions of covered lives either direction. Other large insurers cover both drugs on similar tiers with prior authorization, leaving employer-plan design as the deciding factor more often than the drug itself. Practically: check your plan's own formulary before assuming either brand is the 'easier' one, and don't be surprised if that answer changes with your employer's next plan year.

Side effects — does one hit harder?

Both drugs cause the same family of gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — for the same underlying reason: slowing digestion is the mechanism, not a side issue of it. In SURMOUNT-5, GI-related discontinuation was somewhat more common on semaglutide than tirzepatide, about 5.6% versus 2.7% of participants, even though semaglutide produced the smaller average weight loss. In other words, more people stopped Wegovy specifically because of GI side effects than stopped Zepbound in that trial. Individual tolerance still varies a lot, and trial averages don't predict any one person's experience.

Can you switch from Wegovy to Zepbound (or the reverse)?

Yes, and clinicians make this switch routinely — most often when a plateau shows up, side effects become hard to live with, or (increasingly) a formulary change removes one drug from your coverage overnight. There's no FDA-established dose equivalency between semaglutide and tirzepatide, so a switch isn't a matter of converting your current dose to a matching one on the new drug. In practice, most prescribers restart at the new drug's lowest introductory dose regardless of where you left off — even coming from the maximum semaglutide dose, tirzepatide typically restarts at its lowest level, and the reverse direction works the same way. How the timing and monitoring get handled is worth working through directly with whoever is prescribing, since it varies by provider and by how you responded to the first drug.

What do real people say — Wegovy vs. Zepbound on Reddit and reviews?

Patient communities on Reddit and review sites report a lot of overlap between the two drugs, which makes sense given how similar their mechanisms are. Recurring themes across both: appetite suppression — often described as quieter "food noise" — that some people find fades before their next weekly dose, injection-day fatigue or nausea in the first day or two after a dose increase, and a preference split between the KwikPen's click-and-inject simplicity and a vial's lower cost. Hair thinning gets reported with both drugs, generally attributed to rapid weight loss itself rather than either molecule specifically, which lines up with how hair shedding shows up after significant weight change from any method. Take aggregate sentiment for what it is — a pattern across unverified, self-selected posts, not clinical data — and weigh it alongside the trial evidence above, not instead of it.

Wegovy or Zepbound — which is right for you at 40+?

Perimenopause adds its own wrinkle to this decision. Falling estrogen is linked to worsening insulin resistance and a shift toward central, abdominal fat storage, on top of whatever else is reshaping a woman's body and life at midlife. Both drugs act on pathways relevant to that shift — improving insulin sensitivity and quieting appetite signaling — which is part of why obesity-medicine physicians increasingly treat GLP-1 medications as reasonably well matched to the perimenopausal metabolic picture. Neither SURMOUNT-5 nor either drug's approval trial isolated a perimenopausal or postmenopausal subgroup specifically, though, so there's no menopause-specific verdict between the two — just the general head-to-head evidence above, applied to your own situation.

• Budget is the binding constraint → Wegovy. It's cheaper at every self-pay and retail tier, and the oral tablet adds a genuinely lower-cost pathway Zepbound doesn't have.
• You want the strongest average result and cost is secondary → Zepbound. SURMOUNT-5 is the best evidence either drug has for a bigger average outcome, though Wegovy's 7.2mg dose has narrowed that margin since the trial ran.
• Your insurance already covers one of them → let coverage decide. Formulary tilt moves year to year, and fighting a prior authorization for the uncovered drug rarely beats simply using the one your plan already pays for.
• Needles are a hard no → Wegovy's oral tablet is the only pill-form option between the two; Zepbound remains injection-only.
• You've struggled with GI side effects on a GLP-1 before → the SURMOUNT-5 discontinuation data gives Zepbound a slight edge on tolerability, though this varies person to person.